Target type: cellularcomponent
An integrin complex that comprises one alpha11 subunit and one beta1 subunit. [PMID:12297042]
The integrin alpha11-beta1 complex is a transmembrane receptor that plays a crucial role in cell-matrix adhesion. It is a heterodimer composed of two subunits: the alpha11 subunit and the beta1 subunit. The alpha11 subunit is a type I transmembrane protein with a large extracellular domain that contains an I-domain, a metal ion-dependent adhesion site (MIDAS), and several other binding sites for extracellular matrix (ECM) components. The beta1 subunit is a type I transmembrane protein with a smaller extracellular domain that contains a cysteine-rich region and a transmembrane domain.
The integrin alpha11-beta1 complex interacts with a variety of ECM components, including laminin, fibronectin, and collagen. This interaction is mediated by the alpha11 subunit's I-domain and MIDAS. The binding of the integrin alpha11-beta1 complex to ECM components triggers a signaling cascade that activates intracellular pathways involved in cell adhesion, migration, proliferation, and differentiation.
The integrin alpha11-beta1 complex is expressed in a variety of tissues, including epithelial cells, endothelial cells, and smooth muscle cells. It plays a critical role in the development and function of these tissues, including epithelial morphogenesis, angiogenesis, and wound healing.
In addition to its role in cell-matrix adhesion, the integrin alpha11-beta1 complex also interacts with other cell surface receptors, including growth factor receptors and adhesion molecules. These interactions contribute to the complex regulation of cellular behavior.
The integrin alpha11-beta1 complex is a dynamic molecule that can undergo conformational changes in response to binding to ECM components or other cell surface receptors. These conformational changes can alter the affinity of the integrin for its ligands and regulate its signaling activity.
Dysregulation of integrin alpha11-beta1 complex function has been implicated in a variety of diseases, including cancer, fibrosis, and inflammation. Understanding the structure and function of the integrin alpha11-beta1 complex is therefore crucial for developing new therapies for these diseases.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
| 1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
| tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
| arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
| arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
| glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
| d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
| l 738167 | L 738167: structure in first source | ||
| cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
| l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
| cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
| arginyl-glycyl-aspartyl-phenylalanine | |||
| cyclic(arg-gly-asp-d-phe-val) | |||
| mk-0429 | |||
| mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
| tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
| bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |